Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma

(2019) Alexander C. Huang et al.   NATURE MEDICINE

Tumor-localized costimulatory T cell engagement by the 4-1BB/HER2 bispecific antibody-Anticalin fusion PRS-343

(2019) Marlon J Hinner et al.   CLINICAL CANCER RESEARCH

CD40 Agonist Antibodies in Cancer Immunotherapy

(2019) Robert H. Vonderheide   Annual Review of Medicine

A BISPECIFIC MOLECULE TARGETING CD40 AND TUMOR ANTIGEN MESOTHELIN ENHANCES TUMOR-SPECIFIC IMMUNITY

(2019) Shiming Ye et al.   Cancer Immunology Research

Abstract 5621: FAP-4-1BBL: A novel versatile tumor-stroma targeted 4-1BB agonist for combination immunotherapy with checkpoint inhibitors, T-cell bispecific antibodies, and ADCC-mediating antibodies

(2018) Johannes Sam et al.   CANCER RESEARCH

Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma

(2018) David L. Bajor et al.   OncoImmunology

1070PADAPTATION OF THE IMMUNE RELATED RESPONSE CRITERIA: IRRECIST

(2017) O. Bohnsack et al.   ANNALS OF ONCOLOGY

Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire

(2016) David Y. Oh et al.   CANCER RESEARCH

Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists

(2016) Gregory L. Beatty et al.   Expert Review of Anticancer Therapy

IFN  and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma

(2016) K. B. Long et al.   Cancer Discovery

A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma

(2015) A. K. Nowak et al.   ANNALS OF ONCOLOGY

Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy

(2014) I. Pastan et al.   CANCER RESEARCH

A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma

(2013) G. L. Beatty et al.   CLINICAL CANCER RESEARCH

Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements

(2013) M. Nishino et al.   CLINICAL CANCER RESEARCH

Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer

(2013) L. C. Sandin et al.   Cancer Immunology Research

Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors

(2013) Robert H. Vonderheide et al.   OncoImmunology

Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors

(2011) Jens Rüter et al.   CANCER BIOLOGY & THERAPY

Local Activation of CD8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD40 Antibody

(2011) M. F. Fransen et al.   CLINICAL CANCER RESEARCH

CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

(2011) G. L. Beatty et al.   SCIENCE

AdCD40L Immunogene Therapy for Bladder Carcinoma--The First Phase I/IIa Trial

(2010) P.-U. Malmstrom et al.   CLINICAL CANCER RESEARCH

CD40-activated B cells contribute to mesothelioma tumor regression

(2010) Connie Jackaman et al.   IMMUNOLOGY AND CELL BIOLOGY

Molecular mechanism and function of CD40/CD40L engagement in the immune system

(2009) Raul Elgueta et al.   IMMUNOLOGICAL REVIEWS

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Mesothelin targeted cancer immunotherapy

(2007) Raffit Hassan et al.   EUROPEAN JOURNAL OF CANCER